FDA slaps black-box warning on hep C wonder drugs, citing risk of hep B comeback


The market’s revolutionary hep C drugs are getting a black-box warning from the FDA--and while it likely won’t dent sales much, it’s a blemish on a safety record that’s so far been fairly free of serious side effects.

Tuesday, the agency said it would bestow its most serious label warning on a group of direct-acting antivirals (DAA), comprising Gilead’s Harvoni, Sovaldi and Epclusa, AbbVie’s Viekira Pak and Technivie, Merck’s Zepatier, Bristol-Myers Squibb’s Daklinza and Johnson & Johnson’s Olysio.

The reason? The meds increase the risk that a hep B infection could come roaring back in current or previous hep B patients.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

That’s a big problem, U.S. regulators noted, highlighting “a few cases” in which reactivated HBV in patients on DAA therapies caused serious liver problems or death. And so the new cautionary language--which will appear in the products’ medication guides, as well as on their labels--will direct doctors to screen and monitor for HBV in all patients on the new-age hep C fighters.

The crop of so-called wonder drugs has seen record-breaking sales since Gilead rolled out the first--Sovaldi--in late 2013, in part because of near-perfect cure rates. But a lack of side effects has also been a key feature in elevating the drugs over earlier--and cheaper--rivals; difficult-to-tolerate interferon-based regimens patients relied on in the past came along with flu-like symptoms and other unwanted effects for some sufferers.

That’s not to say they’ve all been perfect. Last October, the FDA slapped a warning on Viekira Pak and Technivie, noting that they could cause serious liver injury or death in patients with underlying advanced liver disease.

Meanwhile, the FDA isn’t the only global regulatory body looking into the hep B issue.  In March, the European Medicines Agency said it was taking a look at the situation, and Japan’s Pharmaceuticals and Medical Devices Agency started up its own review later in the spring.

- read the FDA's release

Related Articles:
Japan's PMDA reviews hep B risk link to hep C therapies
FDA warning on AbbVie hep C drugs gut kicks its share price

Suggested Articles

A manufacturing facility that Novartis discarded because of declining generics sales is getting a new life producing CBD products.

Allergan investors have been pushing for action from management, and AbbVie has been hunting for new revenue streams. Now, they're set to combine.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.